X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Mechanism of inert inflammation in an immune checkpoint blockade-resistant tumor subtype bearing transcription elongation defects.

Vishnu Modur | Belal Muhammad | Jun-Qi Yang | Yi Zheng | Kakajan Komurov | Fukun Guo
Cell reports | 2023

The clinical response to immune checkpoint blockade (ICB) correlates with tumor-infiltrating cytolytic T lymphocytes (CTLs) prior to treatment. However, many of these inflamed tumors resist ICB through unknown mechanisms. We show that tumors with transcription elongation deficiencies (TEdef+), which we previously reported as being resistant to ICB in mouse models and the clinic, have high baseline CTLs. We show that high baseline CTLs in TEdef+ tumors result from aberrant activation of the nucleic acid sensing-TBK1-CCL5/CXCL9 signaling cascade, which results in an immunosuppressive microenvironment with elevated regulatory T cells and exhausted CTLs. ICB therapy of TEdef+ tumors fail to increase CTL infiltration and suppress tumor growth in both experimental and clinical settings, suggesting that TEdef+, along with surrogate markers of tumor immunogenicity such as tumor mutational burden and CTLs, should be considered in the decision process for patient immunotherapy indication.

Pubmed ID: 37043352 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


CD8 (antibody)

RRID:AB_2737972

This monoclonal targets CD8

View all literature mentions

CD45 (antibody)

RRID:AB_396609

This monoclonal targets CD45

View all literature mentions

CD223 (antibody)

RRID:AB_11153127

This monoclonal targets CD223

View all literature mentions

H3K36me3-human (antibody)

RRID:AB_306966

This polyclonal targets H3K36me3

View all literature mentions

RNA pol II Antibody (antibody)

RRID:AB_2687513

This monoclonal targets RNA pol II

View all literature mentions

RNA pol II CTD phospho Ser5 antibody (mAb) (antibody)

RRID:AB_2687451

This monoclonal targets RNA pol II CTD phospho Ser5

View all literature mentions

RNA pol II CTD phospho Ser2 antibody (antibody)

RRID:AB_2687450

This monoclonal targets RNA pol II CTD

View all literature mentions

InVivoPlus anti-mouse CTLA-4 (CD152) (antibody)

RRID:AB_10950184

This monoclonal targets CTLA-4 (CD152)

View all literature mentions

InVivoPlus anti-mouse PD-1 (CD279) (antibody)

RRID:AB_10949053

This monoclonal targets PD-1 (CD279)

View all literature mentions

Mouse CCL5/RANTES Affinity Purified Polyclonal Ab (antibody)

RRID:AB_10080077

This monoclonal targets Mouse CCL5/RANTES Affinity Purified Ab

View all literature mentions

PE anti-mouse CXCL9 (MIG) (antibody)

RRID:AB_2245489

This monoclonal targets CXCL9

View all literature mentions

CD8 (antibody)

RRID:AB_2737972

This monoclonal targets CD8

View all literature mentions

CD45 (antibody)

RRID:AB_396609

This monoclonal targets CD45

View all literature mentions